• linkedin
  • Increase Font
  • Sharebar

    AUA '17 puts emphasis squarely on 'value'

    New era of value-based care permeates policy, clinical presentations


    Advanced Prostate Cancer

    J. Brantley Thrasher, MDDr. ThrasherJ. Brantley Thrasher, MD, pointed out several high-interest abstracts related to advanced prostate cancer treatment and prognosis, including a study comparing the time period from initiation of androgen deprivation therapy (ADT) to salvage chemotherapy in African American and Caucasian men with castrate-resistant disease, an investigation of metformin’s effect on survival in men receiving ADT, and multiple studies on whether the addition of radical prostatectomy to surgical castration improves survival in node-positive patients.

    “Attendees will see a number of abstracts reviewing serum testosterone levels prior to and after ADT and the prognostic implications of these levels on patients with advanced disease,” said Dr. Thrasher, professor of urology at the University of Kansas Medical Center, Kansas City. “Also, several abstracts outline the use of radical surgery locally or at distant metastatic sites as an adjunct and the long-term oncologic outcomes. Multiple abstracts address the impact of ADT on multiple metabolic markers and medications that may affect the metabolic changes.”

    Here are Dr. Thrasher's abstract picks in advanced prostate cancer:

    MP53-04: Comparison of the length of time from initiation of androgen deprivation therapy to salvage chemotherapy in African American males and Caucasian males with castrate resistant prostate cancer

    Maria Uloko


    MP53-08: Metformin use is associated with improved survival in veterans with advanced prostate cancer on androgen deprivation therapy

    Kyle Richards


    MP53-16: Long-term oncologic outcomes of adding radical prostatectomy to castration for pathological node-positive prostate cancer

    Bimal Bhindi


    MP53-17: Current management of prostate cancer with node-positive disease after radical prostatectomy and its impact on overall survival

    Alaa Hamada


    MP53-18: Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis

    Thomas Seisen


    PD24-06: Trends in management of bone health in men with metastatic prostate cancer: Analysis from the Surveillance, Epidemiology, and End Results Medicare database

    William R. Boysen


    PD37-04: Statins and oral treatments in patients with metastatic castration resistant prostate cancer (mCRPC): Real-world outcomes

    Nicole Engel-Nitz

    Richard R. Kerr
    Kerr is group content director for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available